Literature DB >> 9260154

Immunotoxins for the treatment of B-cell lymphomas.

M A Ghetie1, V Ghetie, E S Vitetta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9260154      PMCID： PMC2230224     

Source DB:  PubMed          Journal:  Mol Med        ISSN： 1076-1551            Impact factor:   6.354


× No keyword cloud information.
  34 in total

Review 1.  Pokeweed antiviral protein: ribosome inactivation and therapeutic applications.

Authors:  J D Irvin; F M Uckun
Journal:  Pharmacol Ther       Date:  1992       Impact factor: 12.310

2.  The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond.

Authors:  V Ghetie; P Thorpe; M A Ghetie; P Knowles; J W Uhr; E S Vitetta
Journal:  J Immunol Methods       Date:  1991-09-13       Impact factor: 2.303

3.  Phase I immunotoxin trial in patients with B-cell lymphoma.

Authors:  E S Vitetta; M Stone; P Amlot; J Fay; R May; M Till; J Newman; P Clark; R Collins; D Cunningham
Journal:  Cancer Res       Date:  1991-08-01       Impact factor: 12.701

Review 4.  Immunotoxins for the treatment of leukaemia.

Authors:  F M Uckun
Journal:  Br J Haematol       Date:  1993-11       Impact factor: 6.998

5.  Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.

Authors:  S A Shah; P M Halloran; C A Ferris; B A Levine; L A Bourret; V S Goldmacher; W A Blättler
Journal:  Cancer Res       Date:  1993-03-15       Impact factor: 12.701

6.  The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.

Authors:  M A Ghetie; K Tucker; J Richardson; J W Uhr; E S Vitetta
Journal:  Blood       Date:  1992-11-01       Impact factor: 22.113

7.  A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.

Authors:  P L Amlot; M J Stone; D Cunningham; J Fay; J Newman; R Collins; R May; M McCarthy; J Richardson; V Ghetie
Journal:  Blood       Date:  1993-11-01       Impact factor: 22.113

8.  Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest.

Authors:  M A Ghetie; L J Picker; J A Richardson; K Tucker; J W Uhr; E S Vitetta
Journal:  Blood       Date:  1994-03-01       Impact factor: 22.113

9.  Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.

Authors:  F M Uckun; L M Chelstrom; D Finnegan; L Tuel-Ahlgren; C Manivel; J D Irvin; D E Myers; R Gunther
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

10.  Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail.

Authors:  M A Ghetie; K Tucker; J Richardson; J W Uhr; E S Vitetta
Journal:  Blood       Date:  1994-08-01       Impact factor: 22.113
View more
  2 in total

Review 1.  Designing immunotoxins for cancer therapy.

Authors:  Christopher A Pennell; Heidi A Erickson
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Bacterial toxins: friends or foes?

Authors:  C K Schmitt; K C Meysick; A D O'Brien
Journal:  Emerg Infect Dis       Date:  1999 Mar-Apr       Impact factor: 6.883
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.